|
|
|
May 13, 2008
BMS and KAI Enter Global Alliance to Develop and Commercialize KAI-9803 for Cardiovascular Disease
Kai Pharmaceuticals is developing drugs targeting protein kinase C. Kai announced an exclusive agreement with Bristol-Myers Squibb for the global development and commercialization of KAI_9803, the company’s first-in-class inhibitor of the delta protein kinase C pathway. Read more here.
--------------------------------
Back to News
|
|
| |
